摘要
During recent decades, substantial progress has been made in clinical strategies for treating hematological malignancies. Not only did China benefit from the global progression in the management of acute promyelocytic leukemia, risk-stratification-directed strategies for acute or chronic leukemia and haploidentical hematopoietic stem cell transplantation, the unique system developed by Chinese doctors has also become inspiration for refining global clinical practice. The multicenter trials and collaborations adhering to international standards might further strengthen the global impact and lead the way in specific fields of research worldwide.
During recent decades, substantial progress has been made in clinical strategies for treating hematological malignancies. Not only did China benefit from the global progression in the management of acute promyelocytic leukemia, risk-stratification-directed strategies for acute or chronic leukemia and haploidentical hematopoietic stem cell transplantation, the unique system developed by Chinese doctors has also become inspiration for refining global clinical practice. The multicenter trials and collaborations adhering to international standards might further strengthen the global impact and lead the way in specific fields of research worldwide.
基金
supported by the National Natural Science Foundation of China(81230013
81400146
81530046)
the Beijing Municipal Science and Technology Program(Z141100000214011)
关键词
恶性血液病
急性早幼粒细胞白血病
造血干细胞移植
血液系统
临床实践
恶性肿瘤
全球发展
临床试验
hematological malignancy,acute promyelocytic leukemia,acute myeloid leukemia,chronic myeloid leukemia,haploidentical hematopoietic stem cell transplantation
